Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALX Oncology HoldingsALXO +0.51%31 EV-to-EBIT is -1.85 as of Aug. 25, 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, ALX Oncology Holdings ranks worse than 265957.18% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ALX Oncology Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $142.44 Mil.
ALX Oncology Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ALX Oncology Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's EV-to-EBIT falls into.
ALX Oncology Holdings's current Enterprise Value is $146.65 Mil.
ALX Oncology Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALXO) has a EV-to-EBIT of -1.85 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ALX Oncology Holdings and its competitors. According to the industry distribution chart, ALX Oncology Holdings ranks #999999 out of 376 companies in the Biotechnology industry.
Is ALX Oncology Holdings' EV-to-EBIT too high?
ALX Oncology Holdings' current EV-to-EBIT is -1.85. Based on the distribution chart, ALX Oncology Holdings ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' EV-to-EBIT compare to CYDY and BCYC?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #999999 out of 376 companies for EV-to-EBIT. This places ALX Oncology Holdings in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ALX Oncology Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALX Oncology Holdings's current EV-to-EBIT is -1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current EV-to-EBIT of -1.85. The current EV-to-EBIT is -1.85. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current EV-to-EBIT is -1.85 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score
Get the complete analysis for ALXO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
